These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 19818996

  • 1. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD, Choi HS, Kim SM.
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [Abstract] [Full Text] [Related]

  • 2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [Abstract] [Full Text] [Related]

  • 3. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [Abstract] [Full Text] [Related]

  • 4. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA.
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [Abstract] [Full Text] [Related]

  • 5. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T, Hopkins L, Faught W, Fung-Kee-Fung M.
    Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
    [Abstract] [Full Text] [Related]

  • 6. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR.
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 8. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP.
    Clin Cancer Res; 2000 Aug 15; 6(8):3260-70. PubMed ID: 10955812
    [Abstract] [Full Text] [Related]

  • 9. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M, Federico M, Liu PY, Hannigan E, Alberts D.
    Gynecol Oncol; 2006 Oct 15; 103(1):195-8. PubMed ID: 16595148
    [Abstract] [Full Text] [Related]

  • 10. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Acta Obstet Gynecol Scand; 2008 Oct 15; 87(11):1136-42. PubMed ID: 18951217
    [Abstract] [Full Text] [Related]

  • 11. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
    Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ.
    J Natl Cancer Inst; 2011 Sep 07; 103(17):1338-42. PubMed ID: 21840849
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Sep 07; 102(3):432-9. PubMed ID: 16860852
    [Abstract] [Full Text] [Related]

  • 13. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM, Karimi Zarchi M, Ghaemmaghami F, Behtash N, Mousavi AS, Ansaripoor S.
    Gynecol Oncol; 2007 Jun 07; 105(3):780-3. PubMed ID: 17433423
    [Abstract] [Full Text] [Related]

  • 14. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 15. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J.
    Gynecol Oncol; 2010 Mar 01; 116(3):301-6. PubMed ID: 19945740
    [Abstract] [Full Text] [Related]

  • 16. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J.
    Gynecol Oncol; 2010 Mar 01; 116(3):307-11. PubMed ID: 19944452
    [Abstract] [Full Text] [Related]

  • 17. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R.
    Gynecol Oncol; 1995 Jul 01; 58(1):42-7. PubMed ID: 7789889
    [Abstract] [Full Text] [Related]

  • 18. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Ahn WS, Namkoong SE.
    Gynecol Oncol; 2007 Jul 01; 106(1):193-200. PubMed ID: 17466362
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS.
    J Clin Oncol; 2006 Mar 20; 24(9):1454-8. PubMed ID: 16549840
    [Abstract] [Full Text] [Related]

  • 20. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G.
    Acta Obstet Gynecol Scand; 2008 Mar 20; 87(12):1343-52. PubMed ID: 18951208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.